Login / Signup

Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults.

Erik L KimbleRyan D Cassaday
Published in: Leukemia & lymphoma (2021)
Despite improvements in the outcomes of patients with acute lymphoblastic leukemia (ALL), traditional therapies (including hematopoietic stem cell transplant) often still fail. Antigen-specific immunotherapies for the treatment of ALL such as monoclonal antibodies, antibody-drug conjugates, bispecific T-cell engagers (BiTEs), and chimeric antigen receptor (CAR) T-cells have demonstrated remarkable clinical efficacy and are rapidly evolving. With indisputable activity in patients with relapsed or refractory ALL, efforts now hope to integrate these agents into earlier phases of treatment. In this review, we will discuss the available antibody and cellular-based immunotherapies for the treatment of patients with ALL and provide a clinical and biologic framework with which to inform treatment approaches.
Keyphrases
  • acute lymphoblastic leukemia
  • rheumatoid arthritis
  • drug delivery
  • combination therapy
  • hematopoietic stem cell
  • skeletal muscle
  • quality improvement
  • multiple myeloma
  • insulin resistance